Carcinoma, Pancreatic Clinical Trial
Official title:
A Randomized Controlled Phase II Study on Intra-arterial Versus Intravenous Chemotherapy Infusion With Gemcitabine and Oxaliplatin for Locally Advanced Pancreatic Cancer
This study aims to explore the efficacy and safety of intra- arterial infusion of gemcitabine and oxaliplatin in locally advanced pancreatic cancer. This protocol is overseen by the Fudan University Institutional Review Board which has Federal Wide Assurance through the U.S. Department of Health & Human Services (Approved: April 25, 2002).
Primary Outcome Measures:
To compare the overall survival (OS) in patients with locally advanced pancreatic cancer
treated with transcatheter arterial infusion (TAI) of chemotherapeutics or systemic delivered
chemotherapy.
Secondary Outcome Measures:
To compare the progression free survival (PFS), objective response rate (ORR), quality of
life (QoL), and adverse effects of treating locally advanced pancreatic cancer patients with
TAI or systemic chemotherapy.
Exploratory Outcome Measures:
To evaluate the correlation between prognosis and expression of serum microRNAs of the
patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02634502 -
Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis
|
Phase 2 | |
| Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
| Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
| Completed |
NCT04977596 -
Related Studies of Imaging Features and Prognosis Between Pancreatic Neuroendocrine Tumors and Pancreatic Cancer
|
||
| Terminated |
NCT03397342 -
MRI Only Radiation Therapy With CPAP
|
N/A |